 BioSig Technologies Inc NASDAQ:BSGM, which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has increased its patient case goal to at least 1,500 procedures by the end of 2021. BioSigs non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology. 